1. Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate.
- Author
-
Felsenstein KM, Ingalls KM, Hunihan LW, and Roberts SB
- Subjects
- Amyloid beta-Peptides genetics, Amyloid beta-Peptides metabolism, Cells, Cultured, Cholinergic Antagonists pharmacology, Humans, Immunoblotting, Phenotype, Protein Kinase C genetics, Protein Kinase C metabolism, Sweden, Alzheimer Disease genetics, Mutation drug effects, Phorbol 12,13-Dibutyrate pharmacology
- Abstract
Protein phosphorylation mediated by phorbol ester stimulates secretion of the beta-amyloid precursor protein (beta-APP) in the cell culture. This increase in secretion is produced by a transient increase in cleavage to produce non-amyloidogenic protease nexin II products mediated by the alpha-secretase activity, and a concomitant decrease in beta-protein production. Cells expressing the Swedish familial Alzheimer's disease (FAD) variant of beta-APP produce more beta-protein and potentially amyloidogenic fragments than cells expressing wild-type protein; furthermore, cleavage shifts from the alpha- to the beta-secretase cleavage site of the precursor. We show that treatment with phorbol 12,13-dibutyrate (PDBu) of cells expressing the Swedish FAD reverses the mutant phenotype to wild-type. The alpha-secretase cleavage increases with a concomitant loss of beta-protein and other beta-secretase cleaved products. These results show that modulating beta-secretase cleavage directly affects beta-protein production. It suggests that activating protein kinase C through, for example, muscarinic receptor agonists could reduce amyloidosis by modulating the level of beta-protein produced.
- Published
- 1994
- Full Text
- View/download PDF